In a filing, Neumora Therapeutics Inc. revealed its Head of R&D Lenz Robert A. unloaded Company’s shares for reported $0.12 million on Oct 10 ’24. In the deal valued at $15.09 per share,8,260 shares were sold. As a result of this transaction, Lenz Robert A. now holds 314,706 shares worth roughly $-4.91 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Lenz Robert A. sold 5,563 shares, generating $83,507 in total proceeds. Upon selling the shares at $15.01, the Head of R&D now owns 322,966 shares.
Before that, Lenz Robert A. bought 8,260 shares. Neumora Therapeutics Inc. shares valued at $124,603 were divested by the Officer at a price of $15.09 per share.
H.C. Wainwright initiated its Neumora Therapeutics Inc. [NMRA] rating to a Buy in a research note published on October 01, 2024; the price target was $30. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Mizuho began covering NMRA with “an Outperform” recommendation on July 08, 2024. Deutsche Bank started covering the stock on December 12, 2023. It rated NMRA as “a Hold”.
Price Performance Review of NMRA
On Monday, Neumora Therapeutics Inc. [NASDAQ:NMRA] saw its stock jump 0.58% to $15.60. Over the last five days, the stock has gained 7.14%. Neumora Therapeutics Inc. shares have fallen nearly -8.50% since the year began. Nevertheless, the stocks have risen 61.83% over the past one year. While a 52-week high of $21.00 was reached on 03/08/24, a 52-week low of $8.33 was recorded on 06/26/24. SMA at 50 days reached $12.34, while 200 days put it at $12.82.
Levels Of Support And Resistance For NMRA Stock
The 24-hour chart illustrates a support level at 15.11, which if violated will result in even more drops to 14.61. On the upside, there is a resistance level at 16.13. A further resistance level may holdings at 16.65. The Relative Strength Index (RSI) on the 14-day chart is 71.87, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.37, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 13.46%. Stochastics %K at 86.43% indicates the stock is a selling.
How much short interest is there in Neumora Therapeutics Inc.?
A steep rise in short interest was recorded in Neumora Therapeutics Inc. stocks on 2024-09-30, dropping by -0.3 million shares to a total of 9.68 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 9.98 million shares. There was a decline of -3.12%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 10, 2023 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating along with a $26 price target.
